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Abstract
Chromosome abnormalities induces profound alterations in gene expression, leading to var-
ious disease phenotypes. Recent studies on yeast and mammalian cells have demonstrated
that aneuploidy exerts detrimental effects on organismal growth and development, regard-
less of the karyotype, suggesting that aneuploidy-associated stress plays an important role
in disease pathogenesis. However, whether and how this effect alters cellular homeostasis
and long-term features of human disease are not fully understood. Here, we aimed to inves-
tigate cellular stress responses in human trisomy syndromes, using fibroblasts and induced
pluripotent stem cells (iPSCs). Dermal fibroblasts derived from patients with trisomy 21, 18
and 13 showed a severe impairment of cell proliferation and enhanced premature senes-
cence. These phenomena were accompanied by perturbation of protein homeostasis, lead-
ing to the accumulation of protein aggregates. We found that treatment with sodium 4-
phenylbutyrate (4-PBA), a chemical chaperone, decreased the protein aggregates in tri-
somy fibroblasts. Notably, 4-PBA treatment successfully prevented the progression of pre-
mature senescence in secondary fibroblasts derived from trisomy 21 iPSCs. Our study
reveals aneuploidy-associated stress as a potential therapeutic target for human trisomies,
including Down syndrome.
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Introduction
Down syndrome (DS; trisomy 21) is the most common chromosomal abnormality, affecting 1
in 650–1000 births [1]. Most cases of DS have an extra copy of chromosome 21, exhibiting var-
ious types of clinical complications including intellectual disability, congenital heart defects
and hematopoietic abnormalities. These phenotypes are generally thought to be a direct result
of cumulative effects caused by increased expression of a specific subset of genes located on
chromosome 21. Intensive studies have been made to identify the combination of genes
responsible for disease phenotypes, providing clues to decipher the molecular consequences of
genome dosage imbalances. Many features, such as pediatric leukemia in DS, can be clearly
explained by this “gene dosage effects” hypothesis, and several candidate genes have been iden-
tified using cell and animal models [2–4]. However, the clinical presentation of DS is complex
and highly variable, and there seems not always to be a direct correlation between gene dosage
and disease phenotypes, suggesting the existence of different mechanisms that can modify the
gene-specific effect and have a strong impact on DS pathology.
It is commonly accepted that organismal aneuploidy causes growth defects in plants [5], or
embryonic lethality and developmental impairment in metazoans, across species [6, 7]. Studies
on whole-chromosome gains in budding yeast clearly showed that aneuploidy exerted a prolif-
eration defect regardless of the origin of the extra chromosome, and the severity of the pheno-
type tended to scale with the degree of deviation from the euploid karyotype [8–10].
Intriguingly, this impaired proliferation effect was attributed to the karyotypic alteration itself,
that is, to the cumulative effects of many genes that confer no observable phenotype individu-
ally, rather than to the specific effects of a few dosage-sensitive genes on the extra chromosome
[11]. Meta-analysis of gene/protein expression data from aneuploid cells in diverse organisms
has revealed a novel aneuploidy-associated expression signature characteristic of altered
metabolism and stress response [12, 13]. Subsequent studies on budding yeast have demon-
strated that chromosome aneuploidy causes a variety of cellular stresses, including genomic
instability, cell-cycle arrest, and proteotoxic and oxidative stresses, which are described as
aneuploidy-associated stresses [14, 15].
In humans, aneuploidy occurs in more than 5% of pregnancies. Most of these terminate in
utero, and trisomy 21, 18 and 13 are the only autosomal trisomies that are compatible with
livebirth [16]. Among these syndromes, most patients with trisomies 18 and 13 cannot survive
beyond the first year of life, but average life expectancy for trisomy 21 is around 60 years [17,
18]. Importantly, chromosomes 21, 18 and 13 are those which contain the least number of pro-
tein-coding genes, and there seems to be a correlation between life expectancy or the severity
of clinical symptoms and the number of coding genes on a trisomic chromosome. These
results strongly suggest that recognizable phenotypes in individuals with trisomy can be
formed by the synergistic interaction between chromosome-specific effects of dosage-sensitive
genes and aneuploidy-associated stress.
Given the potential roles of aneuploidy-associated stress in human disease, it is critical to
understand whether and how abnormal karyotypes affect cellular physiology in human pri-
mary cells. Here, we analyzed the physiology of human primary fibroblasts derived from
patients with trisomies 21, 18 and 13. All of the trisomy cell lines showed impaired prolifera-
tion, as well as markedly increased populations of senescence-associated beta-galactosidase
(SA-β-gal)-positive cells. Senescent trisomy fibroblasts contained excess amounts of total RNA
and protein, accompanied by a widespread increase of transcription. This amplified transcrip-
tion and protein synthesis caused an alteration of energy metabolism, leading to an excessive
production of reactive oxygen species (ROS), mitochondrial damage, and the accumulation of
protein aggregates, indicating that human trisomies exert common physiological stress. We
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found that sodium 4-phenylbutyrate (4-PBA), a potent chemical chaperone compound, was
able to reduce the accumulation of protein aggregates in trisomy fibroblasts. In addition, the
progression of premature senescence induced by trisomy could be successfully suppressed by
4-PBA treatment in trisomy 21 induced pluripotent stem cell (iPSC)-derived secondary
fibroblasts.
Materials and methods
All in vitro and in vivo studies were approved by the Ethics Committee and Animal Experi-
mental Faculty of Osaka University Graduate School of Medicine.
Cell counting
On day 0, 3×104 cells were seeded into culture plates. Three days after seeding, the number of
cells was counted after detaching them using trypsin-EDTA solution (0.25% (w/v) trypsin, 1
mmol/l ethylenediaminetetraacetic acid (EDTA)-4Na solution; FUJIFILM Wako Pure Chemi-
cal Corporation, Osaka, Japan).
Apoptosis assay
A terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay
was used to assess apoptosis, with an In situ Apoptosis Detection Kit (Takara Bio Inc., Siga,
Japan), in accordance with the manufacturer’s instructions. Nuclei were counterstained with
Hoechst (Dojindo, Kumamoto, Japan). TUNEL-positive cells and total cell number in a field
of view were automatically counted by an IN Cell Analyzer 6000 (GE Healthcare, Little Chal-
font, UK), and the positive ratio was calculated.
SA-β-gal assay
A Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, Inc., Danvers, MA,
USA) was used to assess cellular senescence, in accordance with the manufacturer’s instruc-
tions. Nuclei were counterstained with Hoechst. SA-β-gal-positive cells and total cell numbers
in a field of view were automatically counted by an IN Cell Analyzer 6000, and the positive
ratio was calculated. For assessing the effects of different chemical compounds on cellular
senescence, 3×104 cells were seeded on day 0, cultured with each compound for two weeks,
and the SA-β-gal-positive cell ratio was then calculated. The compounds used in these analyses
included 2 mM sodium 4-PBA, (Sigma-Aldrich, St. Louis, MO, USA), and 2.5 mM N-Acetyl-
L-cysteine (NAC, Sigma-Aldrich).
ROS assay
The level of ROS was assessed as described previously [19]. Briefly, mitochondrial superoxide
was quantified by staining with 5 μM MitoSox red (Thermo Fisher Scientific Inc., Waltham,
MA, USA) for 15 minutes. Mitochondria were stained with 100 nM Mitotracker Green FM
(Thermo Fisher Scientific Inc.) for 15 minutes. The MitoSox/Mitotracker signal ratio was used
to assess the ROS level per mitochondria. All images were collected with an IN Cell Analyzer
6000.
Mitochondrial membrane potential
Mitochondrial membrane potential was assessed with a MITO-ID Membrane potential detec-
tion kit (Enzo Life Sciences Inc., Farmingdale, NY, USA), in accordance with the manufactur-
er’s instructions. All images were collected with an IN Cell Analyzer 6000.
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Aggresome assay
A PROTEOSTAT Aggresome Detection kit (Enzo Life Sciences Inc.) was used to detect aggre-
somes in cells, in accordance with the manufacturer’s instructions. Nuclei were counterstained
with Hoechst. Cytoplasm was stained with HCS CellMask Deep Red Stain (Thermo Fisher Sci-
entific Inc.). All images were collected with an IN Cell Analyzer 6000. To assess the effects of
different chemical compounds on aggregate accumulation, cells were cultured with each com-
pound and aggregate intensities were evaluated. The compounds used in these analyses
included trimethylamine N-oxide (TMAO, Sigma-Aldrich), sodium 4-PBA, Sigma-Aldrich),
geldanamycin (TCI, Tokyo, Japan), 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich), rapa-
mycin (Sigma-Aldrich), and valproic Acid (VPA, FUJIFILM Wako Pure Chemical
Corporation).
Western blotting
Western blotting was performed as described previously, with some modifications [20].
Briefly, cells were lysed with RIPA Buffer (FUJIFILM Wako Pure Chemical Corporation) con-
taining a protease inhibitor mixture (Roche Diagnostics, Basel, Switzerland). Equal amounts of
protein (10 μg) were electrophoresed using 10% sodium dodecyl sulfate-polyacrylamide gels.
Proteins were transferred to polyvinylidene difluoride membranes, washed with Tris-buffered
saline containing 0.05% Triton X-100, and incubated with BlockingOne solution (Nacalai Tes-
que, Kyoto, Japan) for 60 minutes. Rabbit anti Phospho-Rb (1:1,000; Cell Signaling Technol-
ogy, Inc.) was used as the primary antibody. Horseradish peroxidase-conjugated anti-rabbit
IgG antibody (1:5,000; Promega, Madison, WI, USA) was used as the secondary antibody. As a
control, β-actin was detected with the rabbit anti-β-Actin pAb-HRP-DirecT (1:2,000; MBL).
Blots were visualized using Chemi-Lumi One L (Nacalai Tesque).
Immunocytochemistry
Immunocytochemistry was performed as described previously, with some modifications [20].
Mitochondria were stained by exposing cells to MitoTracker Red CMXRos (100 nM, Thermo
Fisher Scientific Inc.) for 15 minutes before fixation with 4% paraformaldehyde/phosphate-
buffered saline (PBS). Cells were then permeabilized with 0.2% Tween 20/PBS for 15 minutes.
Next, cells were blocked with 5% fetal bovine serum (FBS)/PBS for 30 minutes. Cells were then
incubated at 4˚C for 16 hours with rabbit anti-TOM20 (1:100; Santa Cruz Biotechnology, Dal-
las, TX, USA) primary antibody. After washing with PBS, cells were incubated for 60 minutes
with goat anti-rabbit secondary antibody conjugated with Alexa Fluor 488 (1:200; Thermo
Fisher Scientific Inc.). Nuclei were counterstained with Hoechst (Dojindo). Cytoplasm was
stained with HCS CellMask Deep Red Stain (Thermo Fisher Scientific Inc.). All images were
collected with an IN Cell Analyzer 6000.
Isolation and culture of primary human dermal fibroblasts
Primary human dermal fibroblasts were isolated from skin biopsy specimens of four trisomy
21 patients, three trisomy 18 patients, and one trisomy 13 patient as described previously [21].
In addition, three healthy dermal fibroblast cell lines were purchased from Lonza (Walkers-
ville, MD, USA), and Thermo Fisher Scientific Inc. (full details of the samples used in this
study are provided in S1 Table). For all procedures, informed consent was obtained from each
patient’s guardians in accordance with the regulations of the Ethics Committee of Osaka Uni-
versity Hospital. After fibroblasts grew out from the skin specimens and became subconfluent,
the cells were passaged into a new dish (passage 1). Cells were passaged when the culture
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reached approximately 90% confluence. Primary dermal fibroblasts were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) containing 10% FBS (v/v), 2 mM L-glutamine, 100
U/ml penicillin and 100 μg/ml streptomycin [21]. Experiments were conducted before the pas-
sage number reached 10. Karyotype analysis confirmed that all primary trisomy fibroblasts
retained their original trisomy karyotypes (S1A–S1C Fig).
Maintenance and secondary fibroblast-like cell differentiation of human
iPSCs
Human iPSCs were cultured as previously described [2, 22]. In brief, iPSCs were maintained
on mitomycin C (Sigma)-inactivated mouse embryonic fibroblasts in human ES cell medium
consisting of DMEM/F12 (Wako) supplemented with 20% KnockOut Serum Replacement
(Gibco), 2 mM L-alanyl-L-glutamine (Wako), 1% MEM nonessential amino acid solution
(Wako), 0.1 mM 2-mercaptoethanol (Sigma), and 5 ng/mL basic fibroblast growth factor
(Katayama Chemical). Cultures were passaged every 6–8 days either manually or enzymatically
using dispase II (Roche, Basel, Switzerland).
Secondary fibroblast-like cells were differentiated as described previously, with some modi-
fications [23, 24]. Briefly, embryoid bodies made from human iPSCs were cultured for 4 days
in nonadherent cell culture plates in differentiation medium (80% knockout DMEM (KO-D-
MEM; Thermo Fisher Scientific Inc.), 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 20%
FBS, and 1% nonessential amino acids.) Next, the cell aggregates were seeded into gelatin-
coated plates and cultured for an additional 9 days. The outgrowing cell population was used
as secondary fibroblast-like cells after at least two passages, and cultured in the medium
described above. One clone each of a trisomy 21 fibroblast-derived human iPSC line (Tri21
iPSCs) and corrected disomy 21 iPSC line (cDi21 iPSC) was used in the experiments.
Protein synthesis
The Click-iT AHA Alexa Fluor 488 Protein Synthesis HCS Assay Kit (Thermo Fisher Scientific
Inc.) was used to assess protein synthesis, in accordance with the manufacturer’s instructions.
Briefly, cells were cultured for 30 minutes in L-methionine-free medium containing an amino
acid analog of methionine with an azido moiety, and were then fixed. The amino acid analog
was incorporated into proteins during protein synthesis and could be detected using the
“click” reaction. All images were collected with an IN Cell Analyzer 6000, and the relative level
of protein synthesis was analyzed using the IN Cell Developer Toolbox 1.9 software.
Metabolite assays for glucose and lactate
On day 0, 1×105 cells were seeded into culture plates, and the concentrations of glucose and
lactate in the medium were measured using an ABL800 Flex (Radiometer, Copenhagen, Den-
mark). Three days after seeding, the concentrations of glucose and lactate in the medium were
measured again using the same instrument, and the changes from day 0 were calculated. The
results were normalized to the number of cells.
Measurement of RNA and protein amounts in cells
On day 0, 1×105 cells were seeded into 10-cm dishes. Three days after seeding, without chang-
ing the medium, the number of cells was counted after detaching cells from the culture plate
using trypsin-EDTA solution (0.25% (w/v) trypsin, 1 mmol/l EDTA-4Na solution, FUJIFILM
Wako Pure Chemical Corporation). RNA or protein was extracted from 1×105 cells using
NucleoSpin RNA II (Macherey-Nagel, Oensingen, Switzerland) or DC protein assay kits (Bio-
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Rad Laboratories, Hercules, CA, USA), and the total amounts of RNA and protein in 1×105
cells were determined.
Adenosine triphosphate (ATP) concentration
Cellular ATP concentration was determined using an intracellular ATP determination kit
(Toyo B-Net, Tokyo, Japan). To assess changes in intracellular ATP following inhibition of
ATP production, the production was inhibited by oligomycin (2 μM, Cell Signaling Technol-
ogy) for 60 minutes and the associated decreases in intracellular ATP levels were determined
using the intracellular ATP determination kit (Toyo B-Net). The results were normalized to
the number of cells.
Respiration and acidification rate measurements
The respiration and acidification rates of cells were measured using an XF96 Extracellular Flux
Analyzer (Seahorse Bioscience, North Billerica, MA, USA) in accordance with the manufactur-
er’s instructions. Briefly, 2×104 cells were seeded into culture plates in culture medium a day
before measurement. The assay was performed in unbuffered DMEM supplemented with 25
mM glucose, 2 mM glutamate, and 1 mM pyruvate, in accordance with the manufacturer’s
instructions. Cells were preincubated in this assay medium for 1 hour before measurement.
Oxygen consumption values and acidification rates were calculated in accordance with the
manufacturer’s instructions.
Changes in oxygen consumption following specific inhibition of cellular processes such as
RNA synthesis or protein synthesis were assessed as described previously [25]. Briefly, the oxy-
gen consumption rate was monitored over time under baseline conditions as well as in
response to the addition of inhibitors such as actinomycin D (1 μg/ml, Sigma-Aldrich) or
cycloheximide (0.5 μg/ml, Sigma-Aldrich). The results were normalized to the number of cells.
Gene expression assay using NanoString nCounter
Gene expression assays using the nCounter GX Human Cancer Reference Kit (NanoString
Technologies, Seattle, WA, USA) were conducted in accordance with the manufacturer’s
instructions, following the Cell Lysate Protocol. Briefly, 1×105 cells were collected and lysed
using 50 μl of Buffer RLT (QIAGEN, Hilden, Germany). The cell lysate (4 μl) was hybridized
with the Reporter CodeSet (nCounter GX Human Cancer Reference Kit) and the Capture Pro-
beSet, and was processed in accordance with the instructions. Data were normalized using
positive and negative controls that are included in the kit.
Microarrays
For microarray analysis without RNA spike-in controls [26], 50 ng of total RNA was used,
while for analysis with RNA spike-in controls, 100 ng of total RNA containing RNA spike-in
controls (ERCC ExFold RNA Spike-In Mixes, Thermo Fisher Scientific Inc.) was used. The
quality of the total RNA samples was assessed with an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA). Each total RNA sample was reverse-transcribed, and the
resulting cDNA was subjected to in vitro transcription with T7 RNA polymerase to be labeled
with Cy3. Cy3-labeled cRNAs at 1,650 ng (for analysis without RNA spike-in controls) or 600
ng (for analysis with RNA spike-in controls) were subjected to hybridization, rinsing, scanning
and expression analysis using Agilent Whole Human Genome Microarrays (Human GE
4x44K V2 for analysis without RNA spike-in controls, SurePrint G3 Human GE 8x60K v2 for
analysis with RNA spike-in controls). For data normalization, we used 75th percentile
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normalization for analysis without RNA spike-in controls, while for analysis with RNA spike-
in controls, data were normalized using the median value for ERCC spike-in probes in each
dataset [27]. Raw reads from these samples have been submitted to the Gene Expression
Omnibus database of National Center for Biotechnology Information (accession no.
GSE120291).
Clustering analysis of microarray data
To conduct clustering analysis of microarray data, the distance matrix was calculated using
Euclidean distance with the “ClassDiscovery” software package, version 3.3.7. Clustering anal-
ysis was performed with the hclust function in the “stats” package, version 3.2.4, using all
genes or only genes on the disomic chromosomes [8].
Statistical analyses
All statistical analyses were performed using R version 2.14.0 (http://www.r-project.org) soft-
ware. Comparisons were made by Student’s t-test or Welch’s two-sample t-test. P< 0.05 was
considered to be significant. Data and graphs are expressed as the mean ± standard deviation.
Results
Chromosome trisomies impair cellular proliferation and cause premature
senescence in human fibroblasts
In addition to chromosome-specific effects, aneuploidy has been reported to cause cellular
stress in several species such as budding and fission yeast, and in mouse cells (aneuploidy-asso-
ciated stresses) [7, 8, 14, 28, 29]. To examine whether these general effects can be extensively
observed in naturally occurring human aneuploidies, we collected seven lines of human fibro-
blasts from autosomal trisomy syndromes (three lines from trisomy 21, three lines from tri-
somy 18, and one line from trisomy 13) and three lines from control donors, and analyzed the
cell physiology of these primary fibroblasts. Trisomy 21 fibroblasts showed slower proliferation
than controls, as previously reported [30, 31], and even more severe impairment was observed
in the proliferation of cell lines with trisomy 18 and 13 (Fig 1A). TUNEL-positive cells were
significantly increased in trisomy 21, but the difference was relatively small, and no similar
change was seen in trisomy 18 and 13 cells, suggesting that apoptotic cell death was not the pri-
mary cause of reduced proliferation in trisomy cells (Fig 1B). Notably, all trisomy cell lines
showed markedly increased populations of SA-β-gal-positive cells (Fig 1C). Suppression of
phospho-Rb was also observed in trisomy cells (Fig 1D). These results are consistent with pre-
vious studies showing the association between aneuploidy and cellular senescence [32–35].
The severity of proliferation defects, the percentage of SA-β-gal-positive cells, and the expres-
sion changes in senescence-associated molecules were more obvious in trisomy 18 and 13
cells, but relatively mild in trisomy 21 cells. These results suggest that chromosome aneuploidy
induces common physiological phenotypes, which are associated with the numbers of the
genes located on the affected chromosomes.
Cellular RNA and protein contents are increased in senescent trisomy
fibroblasts
Premature senescence is induced by various types of cellular stress mechanism [36, 37]. Tri-
somy fibroblasts undergoing accelerated premature senescence exhibited enlarged, flattened
and irregular shapes, and these cells contained more than twice the amounts of total RNA as
control cells (Fig 2A). In addition, cellular protein amounts and synthesis ratios were markedly
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Fig 1. Trisomy fibroblasts showed severe proliferative impairment owing to premature senescence. (A) Absolute cell numbers three days after seeding
3×104 cells (n = 3 per cell line). ��P< 0.01. Dip, diploid; Tri, trisomy. (B) Percentage of TUNEL-positive cells (n = 3–7 per cell line). �P< 0.05. Dip, diploid; Tri,
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increased in trisomic cells, compared with those in diploid fibroblasts (Fig 2B and 2C). Protein
synthesis in trisomy 18 cells showed a consistently increasing trend, although the increase was
marginally significant, possibly because of the variability among these trisomy cells. To explore
global gene expression, microarray analysis was performed. The expression levels of genes on
trisomic chromosomes (chromosome 13, 18 or 21) were increased approximately 1.5-fold on
average compared with diploid cells, as expected (Fig 2D). Intriguingly, small but distinct lev-
els of global transcriptional upregulation were observed even for genes on non-trisomic (diso-
mic) chromosomes.
In general, transcriptional analysis is conducted under the assumption that equivalent
amounts of RNA are produced per cell. However, it has been reported that introducing similar
amounts of total RNA from cell extracts into the experimental platform and applying standard
normalization methods may mask the widespread increase of transcription (transcriptional
amplification) and lead to an erroneous interpretation when the total level of mRNA is differ-
ent between the cell lines under comparison [27, 38]. To perform a more robust transcriptional
analysis, we added extrinsic spiked-in RNA standards to total RNA extracts in proportion to
the number of cells, and the microarray datasets were normalized using these spiked-in con-
trols. As reported in S2 Fig, we obtained similar results after normalization with the spiked-in
controls. Hierarchical cluster analysis of the microarray data indicated relative similarity in
gene expression among cells of the same karyotype, and differences between diploid, trisomy
21 and trisomy 18. Notably, the differences were conserved when only genes encoded on chro-
mosomes other than 18 and 21 were analyzed, suggesting that chromosome trisomy affects the
global gene expression pattern (Fig 2E). This transcriptional amplification was confirmed by
NanoString’s nCounter analysis system, in which multiplexed gene expression levels were
directly detected without enzymatic reactions [39]. mRNA levels/cell were quantified for 234
genes encoded on various chromosomes other than chromosome 21. The results showed that
transcripts from 173 genes (73.9%) were expressed at reliable levels in all three diploid cell
lines, and mean gene expression levels were higher in senescent trisomy 21 fibroblasts, with an
average 2.2-fold increase in expression (Fig 2F). These results indicate that gene transcription
and protein synthesis are globally amplified in senescent trisomy fibroblasts.
Energy metabolism is disturbed in senescent trisomy fibroblasts
Amplified global gene transcription and increased protein synthesis might alter energy metab-
olism in senescent trisomy fibroblasts. Indeed, extracellular glucose uptake measurements
revealed markedly increased glucose consumption by senescent trisomy cells. In agreement
with increased glucose consumption, these trisomy fibroblasts showed increased lactate pro-
duction (Fig 3A). Intracellular ATP levels were markedly increased in trisomy fibroblasts, and
inhibition of ATP production by treatment with oligomycin resulted in a significantly greater
reduction in ATP concentration in trisomy 21 cells, suggesting their accelerated consumption
of ATP (Fig 3B and S3A Fig). Measurements of the oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR) on same population of cells showed that they exhibited
accelerated utilization of glycolysis and oxidative phosphorylation (Fig 3C). Furthermore, inhi-
bition of RNA or protein synthesis by treatment with actinomycin D or cycloheximide showed
a pronounced decrease of OCR values in trisomy 21 fibroblasts (albeit not statistically signifi-
cant in data from the RNA synthesis inhibition assay) (S3B Fig). These results suggest that
trisomy; N.S., not significant. (C) Percentage of SA-β-gal-positive cells (n = 3 per cell line). The right panel shows representative phase contrast images.
Bar = 100 μm. ��P< 0.01; �P< 0.05. Dip, diploid; Tri, trisomy. (D) Expression of phospho-Rb by western blotting analysis. Comparisons were made by
Student’s t-test or Welch’s two-sample t-test.
https://doi.org/10.1371/journal.pone.0219592.g001
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global gene transcriptional amplification and accelerated protein synthesis cause disturbed cel-
lular energy metabolism in senescent trisomy fibroblasts.
Chromosome aneuploidy causes oxidative stress and mitochondrial
damage
Activated intracellular energy metabolism can lead to constitutive generation of ROS [40].
Analysis of ROS production using an oxidant-sensitive fluorogenic probe revealed an excessive
production of ROS in all three trisomy lines (Fig 4A). In addition, the total cross-sectional
areas of mitochondria per cell were significantly increased in trisomy fibroblasts compared
with disomic controls, and mitochondrial membrane potential was severely decreased in all
the trisomy lines (Fig 4B and 4C) [19]. Notably, the alterations in both mitochondrial mass
and membrane potential observed in trisomy 18 and 13 were even more severe than those in
trisomy 21. These results suggest that autosomal chromosome trisomy exerts oxidative stress
and mitochondrial damage in fibroblasts.
A chemical chaperone reduces the accumulation of protein aggregates in
trisomy fibroblasts
Oxidative stress has an important role in protein homeostasis. A moderate oxidant concentra-
tion increases proteasomal degradation, whereas persistent and higher oxidant levels lead to
proteolytic inhibition and the accumulation of misfolded protein [41–43]. To examine the
intracellular effects of dysregulated protein homeostasis in trisomy cells, aggregated protein
was detected using an aggregation-sensitive molecular rotor dye [44]. Red fluorescent foci
were localized largely in the cytoplasm, and trisomy cells showed obviously greater aggregation
(Fig 5A). Moreover, signal intensities were significantly higher in trisomy 21, 18 and 13 cells,
suggesting that the severity of trisomy-induced cellular stress affects the level of aggregate for-
mation (Fig 5B).
Since the accumulation of misfolded proteins is associated with several human diseases, this
process is considered to be a potential therapeutic target [45, 46]. To examine whether pre-
venting the formation and/or removal of protein aggregates can ameliorate the various patho-
logical phenotypes observed in trisomy syndromes, fibroblasts were cultured with several
chemical compounds, and aggregate intensities were then evaluated. Protein aggregation levels
were elevated in trisomy 21 fibroblasts, and most of the compounds tested were not only inef-
fective, but even exacerbated the production of aggregates (Fig 5C). However, sodium 4-PBA,
a potent chemical chaperone, decreased aggregate formation without showing any harmful
effects. This effect was further tested in the other trisomy fibroblast lines, and administration
of 4-PBA exhibited remarkable aggregate-reducing effects in a concentration-dependent man-
ner (Fig 5D, S4 Fig).
Fig 2. Senescent trisomy fibroblasts showed increased cellular RNA and protein contents. (A) Cellular RNA content in 1×105 cells (n = 3–16 per cell
line). �P< 0.05. Dip, diploid; Tri, trisomy. (B) Cellular protein content in 1×105 cells (n = 3–6 per cell line). �P< 0.05. Dip, diploid; Tri, trisomy. (C)
Relative protein synthesis ratio per cell, as assessed by the Click-iT AHA Alexa Fluor 488 Protein Synthesis HCS Assay Kit (n = 6–12 per cell line).
�P< 0.05. Dip, diploid; Tri, trisomy. (D) Boxplots of relative log expression ratios for the genes on each chromosome using microarray data without the
spike-in control. The left panel shows data for trisomy 21 fibroblasts compared with control fibroblasts. The middle panel shows data for trisomy 18
fibroblasts compared with the controls. The right panel shows data for trisomy 13 fibroblasts compared with the controls. The upper horizontal lines
indicate a ratio of 1.5 (= 0.58 in log2 scale), while the lower horizontal lines indicate a ratio of 1.0 (= 0 in log2 scale). Dip, diploid; Tri, trisomy. (E)
Hierarchical cluster analysis of microarray data with the spike-in control. The left panel shows a cluster dendrogram using all genes. The right panel
shows a cluster dendrogram using only genes on the disomic chromosomes. Dip, diploid; Tri, trisomy. (F) Gene expression levels as assessed by
NanoString’s nCounter analysis system. �P< 0.05. Dip, diploid; Tri, trisomy. Comparisons were made by Student’s t-test or Welch’s two-sample t-test.
https://doi.org/10.1371/journal.pone.0219592.g002
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Fig 3. Senescent trisomy fibroblasts showed increased glucose consumption and increased lactate production,
suggesting disturbed energy metabolism. (A) The left panel shows relative glucose consumption by 1×105 cells over three
days, as assessed by decreased glucose content in the culture medium. The right panel shows relative lactate production by
1×105 cells over three days, as assessed by increased lactate content in the culture medium (n = 3 per cell line). �P< 0.05.
Dip, diploid; Tri, trisomy. (B) Relative cellular ATP content, as assessed by an intracellular ATP determination kit (n = 4
per cell line). �P< 0.05. Dip, diploid; Tri, trisomy. (C) The left panel shows oxygen consumption rate (OCR), as assessed
by an XF96 Extracellular Flux Analyzer. �P< 0.05. The right panel shows extracellular acidification rate (ECAR), as
assessed by an XF96 Extracellular Flux Analyzer (n = 3–6 per cell line). ��P< 0.01. Dip, diploid; Tri, trisomy.
Comparisons were made by Student’s t-test or Welch’s two-sample t-test.
https://doi.org/10.1371/journal.pone.0219592.g003
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Fig 4. Trisomy fibroblasts showed increased oxidative stress and accumulation of damaged mitochondria. (A)
Relative ROS production as expressed by relative MitoSOX/MitoTracker ratio (n = 5–6 per cell line). �P< 0.05. Dip,
diploid; Tri, trisomy. (B) Relative mitochondrial mass per cell as assessed by average TOM20-positive area per cell. The
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Premature senescence can be rescued by 4-PBA in trisomy 21 iPSC-derived
secondary fibroblasts
Since several human diseases are caused by defects in protein folding, reduction or removal of
protein aggregates may ameliorate the pathological phenotype. Premature senescence is
thought to be triggered by various types of stimuli, and then locked into irreversible growth
arrest by epigenetic alteration [47]. To investigate whether pretreatment with 4-PBA delayed
or prevented the induction of trisomy-associated premature senescence, we used trisomy 21
fibroblast-derived human iPSCs (Tri21 iPSCs) and secondary fibroblasts. To exclude effects of
the genetic background, we used a corrected disomy 21 iPSC line (cDi21 iPSC) as a control, in
which a single copy of chromosome 21 was removed from a Tri21 iPSC line using chromo-
some editing technology [22]. These two iPSC lines perfectly share the same genetic back-
ground, enabling an ideal comparison of cellular phenotypes.
Both iPSC lines showed only sparse (less than 0.2%) SA-β-gal-positive cells, indicating that
epigenetic modification and cellular senescence were reset in the process of reprogramming
(S5 Fig). These cell lines were then differentiated into secondary fibroblasts, to evaluate the
development of senescence [23]. In the early differentiation stage at passage 6, there were no
differences in the ratio of SA-β-gal-positive cells between Tri21 and cDi21 cell lines, indicating
that the cells had not entered the senesced state yet (Fig 6A). In the differentiation process of
pluripotent stem cells, the cellular metabolic system is known to dramatically change from gly-
colysis to oxidative phosphorylation, which is accompanied by increased oxygen consumption
and reactive oxygen species levels. Reflecting this change, an elevation of ROS in trisomy 21
cells was not evident at P6, but became apparent at P8 (Fig 6B). Even at this early point, the
accumulation of protein aggregates was significantly higher in Tri21 cells compared with
cDi21 cells at passage 6 (Fig 6C). In addition, increased mitochondrial mass and reduced mito-
chondrial membrane potential indicated that trisomy-induced stress had already affected the
cells by this passage number (Fig 6D). At an advanced differentiation stage (P11), premature
senescence as a cellular phenotype became evident in Tri21-derived secondary fibroblast cells
(Fig 6A).
On the basis of our finding that 4-PBA effectively eliminates protein aggregates in fibro-
blasts, this compound was applied to cDi21/Tri21-derived secondary fibroblasts from the
point of passage 6. Protein aggregates levels were significantly elevated in untreated Tri21 cells,
but dramatically decreased to the same levels in cDi21 cells when treated with 4-PBA (Fig 6E).
Notably, the ratio of SA-β-gal-positive cells among Tri21 secondary fibroblasts, which was sig-
nificantly increased at this stage, was successfully suppressed to the same level as that in cDi21
cells (Fig 6F). In contrast, no significant decrease of the SA-β-gal-positive cell ratio was
observed in NAC-treated Tri21 secondary fibroblasts, suggesting that prevention of protein
aggregation may be a more potent therapeutic target compared with the oxidative stress path-
way. These results suggest that 4-PBA may be useful for the prevention of premature senes-
cence caused by the trisomy-induced stress.
Discussion
Cellular responses to karyotypic alteration have been intensively investigated in various experi-
mental models such as yeast, mice and humans [7, 10, 14, 48]. These studies demonstrated that
upper panels show representative phase contrast images in which mitochondria were stained with MitoTracker.
Bar = 50 μm. The lower panel shows corresponding quantification (n = 3–8 per cell line). ��P< 0.01. Dip, diploid; Tri,
trisomy. (C) Relative mitochondrial membrane potential per cell (n = 5–10 per cell line). ��P< 0.01. Dip, diploid; Tri,
trisomy. Comparisons were made by Student’s t-test.
https://doi.org/10.1371/journal.pone.0219592.g004
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aneuploidies with different sets of chromosomes exert common proteotoxic stress and cause
transcriptional and/or posttranscriptional alteration, leading to defects in multiple biological
processes [8, 29, 49]. To extend these important insights, we collected human fibroblasts from
patients with autosomal trisomy syndromes (Patau syndrome, trisomy 13; Edwards syndrome,
trisomy 18; Down syndrome, trisomy 21) and examined the pathophysiological mechanisms
shared by these syndromes. Trisomy fibroblasts showed common proliferation defects and
accelerated premature senescence, consistent with earlier results in yeast [15]. These cells were
large, flattened, and contained increased amounts of RNA and proteins. Interestingly, this bio-
logical response was accompanied by the global upregulation of non-trisomic gene expression,
which could be uncovered using extrinsic spike-in standards for normalization. Transcrip-
tional amplification, an increase in global levels of mRNAs, has been implicated in tumors,
heart failure and aging [50–52]. Several transcriptional regulators that bind to promoters or
enhancers, such as c-Myc, have been thought to play a central role in these phenomena. How-
ever, the gene sets located on chromosomes 21, 18 and 13 are different, and therefore, there
are no common dosage alterations in transcriptional regulators between these trisomies. In
senescing trisomy fibroblasts, each chromosome-specific dosage-dependent expression of tri-
somic genes is a first step, and increased expression of several hundreds of genes may then
stimulate larger-scale transcriptional network responses, leading to the activation of various
transcription regulating proteins, rather than responses being mediated by the specific actions
of a few regulators such as c-Myc. At present, it is unclear whether this altered gene expression
is a primary cause or simply an effect of premature senescence. However, we have observed
similar upregulation of RNA/protein synthesis in other differentiated cells that do not exhibit
premature senescence, suggesting that upregulated expression may be involved in the patho-
logical mechanism in trisomy fibroblasts, and not be a mere consequence of senescence
(unpublished data).
Our microarray data demonstrated that the extra chromosome in trisomy 13 cells was not
expressed as highly as the others. The karyotype analysis confirmed that all primary trisomy
fibroblasts retained their original trisomy karyotypes. It was possible that minor mosaicism,
which was not revealed by the karyotype analyses, could explain the finding. However, another
possible explanation was that, while chromosomal dosage compensation has only been estab-
lished for sex chromosomes, previous studies have also found that dosage compensation of
aneuploidy can occur for autosomes [53, 54]. The suggested mechanisms include feedback reg-
ulation for each single gene and an unknown protein that can buffer the expression of the
genes on extra chromosomes, an example of which is the POF protein for the fourth chromo-
some in Drosophila melanogaster [53, 54]. Further study is needed to investigate the gene
expression levels on the extra chromosome and possible mechanism of the modified expres-
sion on the extra chromosomes using human trisomy 13 cells.
Fig 5. Accumulation of aggregated proteins and effect of the chemical chaperone, 4-PBA in trisomy fibroblasts.
(A) Accumulation of aggregated proteins, as detected by the PROTEOSTAT Aggresome Detection kit. Bar = 50 μm.
Dip, diploid; Tri, trisomy. (B) Corresponding quantification of aggregated protein accumulation (n = 5–6 per cell line).
�P< 0.05. Dip, diploid; Tri, trisomy. The left panel shows the result for the comparison between diploid and trisomy
21 cell lines. The right panel shows the result for the comparison between diploid and trisomy 18 and 13 cell lines. (C)
Quantification of aggregated protein accumulation after culture in the presence of six chemical compounds: GA,
geldanamycin; CYD, 2-hydroxypropyl-β-cyclodextrin; RAPA, rapamycin; VPA, valproic acid sodium salt; TMAO,
trimethylamine N-oxide; PBA, sodium phenylbutyrate. Dip, diploid; Tri, trisomy. (D) Effects of sodium
phenylbutyrate on aggregated protein accumulation (mean of three cell lines for Dip, Tri21, and Tri18 fibroblasts;
n = 3 per cell line). Comparison of trisomy samples without PBA with diploid samples without PBA, †P< 0.05.
Comparison of samples with PBA with samples without PBA, �P< 0.05, ��P< 0.01. PBA, sodium phenylbutyrate;
Dip, diploid; Tri, trisomy; N.S., not significant.
https://doi.org/10.1371/journal.pone.0219592.g005
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Fig 6. Rescue of trisomy-induced premature senescence by 4-PBA treatment in trisomy 21 iPSC-derived secondary fibroblasts. (A)
Percentage of SA-β-gal-positive cells (n = 3 per cell line). ��P< 0.01. cDi21, corrected disomy 21 iPSC-derived secondary fibroblasts; Tri21,
trisomy 21 iPSC-derived secondary fibroblasts; N.S., not significant. (B) Relative ROS production as expressed by relative MitoSOX/MitoTracker
ratio at passage 6 (left) and passage 8 (right) (n = 6 per cell line). ��P< 0.01. cDi21, corrected disomy 21 iPSC-derived secondary fibroblasts;
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Increased energy demand to synthesize excessive amounts of RNA and protein should
impose a metabolic burden on trisomy cells, followed by mitochondrial dysfunction and ROS
production that was similarly observed in aneuploid yeast cells [12, 13]. Consistent with a pre-
vious study, ROS levels were significantly increased in the trisomy 21 cells [55]. Although ROS
levels in trisomy 13 cells could not be statistically evaluated due to the lack of cell lines, ROS
production was similarly elevated in trisomy 18 cells, suggesting the existence of a trisomy-
induced stress effect.
Aneuploidy-associated stress is closely related to the total dosage of gene expression, and
the numbers of trisomic genes are generally thought to affect the severity of the stress. There-
fore, trisomies of chromosomes 13 and 18, which contain ~500 and ~400 genes, respectively,
can exert more detrimental effects than that of chromosome 21, which harbors ~300 genes.
This non-specific, but dose-dependent, stress action makes it even more difficult to under-
stand the pathological mechanisms of trisomies. Nevertheless, its dose-dependency might
explain, at least partly, why only fetuses with trisomies of chromosomes 21, 18, and 13, which
have the least numbers of genes among all autosomal chromosomes, can survive to birth, and
other trisomies are embryonic lethal, and why patients with trisomy 21 can live until 60 years
of age on average.
Levels of ROS in fibroblasts with trisomy 18 were not statistically different from those in
fibroblasts with trisomy 21. Such fluctuation was similarly observed in the cellular protein
amount. Because any phenotype observed in trisomy cells results from the synergistic combi-
nation of the gene dosage effects and aneuploidy-associated stress, such discrepancy may result
from the dosage effect caused by specific genes on trisomic chromosome. In this study, the
aneuploidy-associated stress was simply defined as the common phenomena shared by three
trisomies, regardless of those with different severities. To test the hypothesis, further experi-
ments using trisomy 13 and 18 iPSC-derived secondary fibroblasts will be required as the next
step.
Excessive ROS cause structural changes and misfolding of proteins, giving rise to the accu-
mulation of insoluble and nondegradable cross-linked aggregates [56]. A proportional rela-
tionship exists between the amount of protein aggregates and the progression of aging, and
more directly, the incubation of cells with artificial or isolated protein aggregates inhibits pro-
teasome activity, causing some features of premature senescence [57, 58]. We therefore
focused on the toxicity caused by these protein aggregates, and explored chemical compounds
that might effectively reduce trisomy-associated protein aggregation.
A chemical chaperone, 4-PBA has hydrophobic regions that interact with exposed hydro-
phobic segments of an unfolded protein. This interaction promotes correct folding and struc-
ture stabilization of proteins under normal conditions. Under stress conditions, chaperones
can act early in the aggregation process to maintain the solubility of disease proteins and pre-
vent undesirable degradation and/or aggregation [59]. In our experiments, 4-PBA rapidly
attenuated the levels of protein aggregates both in trisomy fibroblasts and in secondary
Tri21, trisomy 21 iPSC-derived secondary fibroblasts; N.S., not significant. (C) Accumulation of aggregated proteins, as detected by the
PROTEOSTAT Aggresome Detection kit (n = 6 per cell line). �P< 0.05. cDi21, corrected disomy 21 iPSC-derived secondary fibroblasts; Tri21,
trisomy 21 iPSC-derived secondary fibroblasts. (D) The left panel shows relative mitochondrial mass per cell as assessed by the mean MitoTracker
Red CMXRos-positive area per cell. The right panel shows relative mitochondrial membrane potential per cell (n = 6 per cell line). ��P< 0.01.
cDi21, corrected disomy 21 iPSC-derived secondary fibroblasts; Tri21, trisomy 21 iPSC-derived secondary fibroblasts. (E) Effects of 4-PBA on
aggregated protein accumulation (n = 5 per cell line). �P< 0.05. PBA, sodium phenylbutyrate; cDi21, corrected disomy 21 iPSC-derived
secondary fibroblasts; Tri21, trisomy 21 iPSC-derived secondary fibroblasts; N.S., not significant. (F) Effects of 4-PBA (2 mM) or NAC (2.5 mM)
on cellular senescence. The right panel shows representative phase contrast images. Bar = 100 μm. The left panel shows corresponding
quantification (n = 3 per cell line). �P< 0.05. PBA, sodium phenylbutyrate; NAC, N-acetyl-L-cysteine; cDi21, corrected disomy 21 iPSC-derived
secondary fibroblasts; Tri21, trisomy 21 iPSC-derived secondary fibroblasts; N.S., not significant.
https://doi.org/10.1371/journal.pone.0219592.g006
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fibroblasts differentiated from Tri21 iPSCs. Intriguingly, administration of 4-PBA efficiently
reverted the percentages of SA-β-gal-positive cells in differentiated Tri21 secondary fibroblasts,
indicating that aneuploidy-associated stress might be a potential therapeutic target for the
pathogenic features of Down syndrome.
Although the toxic effects of protein aggregates on cell viability are evident, whether the
suppressive action of 4-PBA on premature senescence was directly attributable to decreased
protein aggregation or to some other unique mechanism is unclear. In addition to its primary
effect as a chaperone, 4-PBA also acts as a histone deacetylase inhibitor and regulates the tran-
scription of many genes involved in the protein quality control system. Previous studies have
reported that 4-PBA treatment induces dramatic alterations in the gene expression pattern,
including upregulation of genes specifically involved in molecular chaperoning, such as heat
shock proteins, and downregulation of genes involved in metabolic pathways [60, 61]. Overall
generalized changes in epigenetic regulation by 4-PBA may induce fine-tuning of transcrip-
tional regulation, leading to an advantageous effect in this regard.
The effects of 4-PBA in inhibiting aggregate formation in cultured cells and its therapeutic
potency in disease models have been proven in various types of experiments [62, 63]. 4-PBA is
a blood–brain barrier-permeable and orally bioavailable drug, and importantly, has already
been approved by the US Food and Drug Administration for the treatment of urea cycle disor-
ders. Further study will be required to elucidate to what extent aneuploidy-associated stress is
mechanistically involved in the various complications of Down syndrome, including neural
dysfunction, and whether 4-PBA is effective for each phenotype.
Supporting information
S1 Fig. Karyotype analyses of primary trisomy fibroblasts. (A) Karyotype analysis of pri-
mary trisomy 21 fibroblasts. (B) Karyotype analysis of primary trisomy 18 fibroblasts. (C) Kar-
yotype analysis of primary trisomy 13 fibroblasts.
(TIF)
S2 Fig. Relative log expression ratios for genes on each chromosome using microarray data
with the spike-in control. The left panel shows boxplots of the relative log expression ratios of
genes on each chromosome in trisomy 21 fibroblasts as compared with control fibroblasts.
The right panel shows similar data for trisomy 18 fibroblasts compared with controls. The
upper horizontal lines indicate a ratio of 1.5 (= 0.58 in log2 scale), while the lower horizontal
lines indicate a ratio of 1.0 (= 0 in log2 scale). Dip, diploid; Tri, trisomy.
(TIF)
S3 Fig. Senescent trisomy fibroblasts have a disturbed energy metabolism. (A) Decreases in
cellular ATP levels following inhibition of ATP production by oligomycin (2 μM; n = 3 per cell
type). �P< 0.05. Dip, diploid; Tri, trisomy. (B) Left panel, decreases in the oxygen consump-
tion rate (OCR) following inhibition of RNA synthesis using actinomycin D (1 μg/ml). Right
panel, decreases in the OCR following inhibition of protein synthesis using cycloheximide
(0.5 μg/ml; n = 3 per cell line). �P < 0.05. Dip, diploid; Tri, trisomy; N.S., not significant. Com-
parisons were made by the Student’s t-test or Welch’s two-sample t-test.
(TIF)
S4 Fig. Effects of sodium phenylbutyrate on aggregated protein accumulation. Data of
three diploid and three trisomy 21 fibroblast cell lines are shown (n = 3 per cell line; original
data in Fig 5D). �P< 0.05. PBA, sodium phenylbutyrate; Dip, diploid; Tri, trisomy; N.S., not
significant.
(TIF)
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S5 Fig. SA-β-gal expression in iPSCs. Percentages of SA-β-gal positive cells were calculated
for undifferentiated iPSC lines (n = 4 per cell line). cDi21, corrected disomy 21 iPSCs; Tri21,
trisomy21 iPSCs; N.S., not significant.
(TIF)
S1 Table. Characteristics of samples in the present study. Information on sex and age at
sample collection for each patient is shown.
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